免疫治疗与各种手段的联合,已经逐渐取代PD-1/L1抑制剂们早期探索的单药治疗,在某些癌种或适应症上独领风骚。比如在III期肺癌PACIFIC试验中大获成功的PD-L1抑制剂——Durvalumab(简称“I”药),治疗方案就是与放化疗的联合。 而从大局...
靶点 PDL1 作用机制 PDL1抑制剂(程序性死亡配体1抑制剂) 治疗领域 肿瘤消化系统疾病呼吸系统疾病+ [12] 在研适应症 局限期小细胞肺癌子宫癌晚期子宫内膜癌+ [177] 非在研适应症 急性髓性白血病大肠腺癌肺腺癌+ [60] 原研机构 AstraZeneca UK Ltd. ...
1Massard C et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-PD-L1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer. Accepted Manu. To be published June 2016.(抗PD-L1免疫检查站抑制剂durvalumab (MEDI4736)治疗膀胱晚期尿路上皮癌的安全性和有效性。已接受...
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial CancerLisa A. Raedler
- PD-L1 Inhibitor CAS number:1428935-60-7 Medically reviewedby Drugs.com on Sep 20, 2024. Written byASHP. Introduction Antineoplastic agent; recombinant fully human anti-programmed-death ligand-1 (anti-PD-L1) monoclonal antibody. Uses for Durvalumab ...
FDA granted a Breakthrough Therapy designation to AstraZeneca/MedImmune’s monoclonal antibody (mAb) durvalumab, a PD-L1 inhibitor meant to treat patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumors have either progressed or did not respond to platinum-based ch...
1Massard Cet al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-PD-L1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer. Accepted Manuscript. To be published June 2016.(抗PD-L1免疫检查站抑制剂durvalumab (MEDI4736)治疗膀胱晚期尿路上皮癌的安全性和有效性。已...
2 Immune checkpoint inhibitor therapy of cancer ICIs using anti-PD-1, anti-PD-L1, or anti-CTLA-4 are under extensive clinical investigations for treatment of a number of solid tumors. Nivolumab and permbrolizumab are common anti-PD-1 drugs, durvalumab, avelumab and atezolizumab are anti-PD...
Durvalumab (MEDI 4736) 是一种人源化的抗 PD-L1 蛋白单克隆抗体。Durvalumab (MEDI 4736) 完全阻断 PD-L1 与 PD-1 和 CD80 结合, IC50 分别为 0.1 和 0.04 nM。 MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
美国FDA批准施贵宝Opdivo用于非鳞状非小细胞肺癌,成功进入PD-1抑制剂的最大市场。但阿斯列康则因为T790变异EGFR抑制剂AZD9291和PD-L1抗体durvalumab组合在临床试验发现肺间质损伤而暂时中止Tatton和Caural试验。免疫哨卡抑制剂一方面继续显示强劲潜力,但复方组合的不确定性也令投资者热情有所收敛。